BioSpace News Archive

Vaxart, Inc. (“Vaxart” or the “Company”) (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced today announced that Wouter Latour, MD, chief executive officer of Vaxart is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 2:00 p.m. Eastern Time. Jefferies Virtual Health

- DSMB Reviewed Over 500 Patients’ Data in Second Interim Analysis to Assess Overall Benefit / Risk with Plinabulin in Second- and Third-Line, EGFR Wild-Type NSCLC - - Data Continue to Support Plinabulin’s Immune Mechanism-Targeted Patient Selection -

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapies for neurodegenerative diseases, announced Dr. Ralph Kern, M.D, President and Chief Medical Officer will present a corporate overview during the BIO International Convention, which has transitioned to a new and virtual event and has been renamed BIO Digital.

Katana Pharmaceuticals Inc., a San Francisco-based startup biotech company developing novel treatments for neonatal patient populations and rare pediatric disorders, announced the receipt of the first payment of an up to $1.05 million Innovative Challenge Grant from March of Dimes to develop a novel non-opioid treatment for neonatal abstinence syndrome.*

Distributed Bio, a global leader in computational optimization of fully human monoclonal antibody libraries, is pleased to announce a comprehensive research partnership with Mediar Therapeutics, a preclinical stage biotechnology company developing therapeutics to halt, or even reverse, fibrosis based in Cambridge, MA.

Confo Therapeutics announced the appointment of Paolo Vicini, PhD, MBA, in the newly-created position of Chief Development Officer effective June 1, 2020.

Avectas today announced that it has entered into a collaborative agreement with The Simon Laboratory at UC Davis, California, USA (UCD) to engage in the characterisation of cells engineered with Avectas’ proprietary, non-viral SOLUPORE™ cell engineering platform.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from two Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2, which showed that TREMFYA®

Incyte announced that it will present at the following investor conferences during the month of June

Complexa Inc. today announced the completion of patient enrollment in the FIRSTx study, a Phase 2 clinical trial evaluating the safety and efficacy of the company’s lead candidate, CXA-10, to treat primary focal segmental glomerulosclerosis (FSGS).